Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Global market for Gene Therapy estimated at US$970.5 Million in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at a CAGR of 19.5% over the period 2020-2027.
Viral, one of the segments analyzed in the report, is projected to grow at a 19.7% CAGR to reach US$3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Viral segment is readjusted to a revised 17.6% CAGR for the next 7-year period. This segment currently accounts for a 11.1% share of the global Gene Therapy market.
The U.S. Accounts for Over 53.7% of Global Market Size in 2020, While China is Forecast to Grow at a 25.1% CAGR for the Period of 2020-2027
The Gene Therapy market in the U.S. is estimated at US$521.3 Million in the year 2020. The country currently accounts for a 53.71% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$107.9 Million in the year 2027 trailing a CAGR of 25.1% through 2027.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.3% and 18.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 18.6% CAGR while Rest of European market (as defined in the study) will reach US$107.9 Million by the year 2027.
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
-
Influencer Market Insights
-
World Market Trajectories
-
Impact of Covid-19 and a Looming Global Recession
-
A Prelude to Gene Therapy
-
Classification of Gene Therapies
-
COVID-19 Causes Gene Therapy Market to Buckle & Collapse
-
COVID-19 Impact on Different Aspects of Gene Therapy
-
Manufacturing & Delivery
-
Research & Clinical Development
-
Commercial Operations & Access
-
Managing Derailed Operations
-
Focus on Clinical Development Programs
-
Targeting Manufacturing & Delivery Strategies
-
Securing Supplies
-
Remote Working
-
Gene Therapy Set to Witness Rapid Growth Post COVID-19
-
By Vector Type
-
Viral Vectors Account For A Major Share Of The Market
-
Adeno-Associated Virus Vectors
-
Lentivirus
-
Non-Viral Vectors To Witness Faster Growth
-
US and Europe Dominate the Gene Therapy Market
-
Oncology Represents the Largest Indication for Gene Therapy
-
Market Outlook
-
WORLD BRANDS
2. FOCUS ON SELECT PLAYERS
-
Recent Market Activity
-
Select Innovations
-
Abeona Therapeutics Inc.
-
Adaptimmune Therapeutics Plc
-
Advantagene, Inc.
-
Adverum Biotechnologies, Inc
-
Akcea Therapeutics
-
Alnylam Pharmaceuticals, Inc.
-
Amgen Inc
-
Anchiano Therapeutics, Inc.
-
AnGes, Inc.
-
Applied Genetic Technologies Corporation
-
Audentes Therapeutics, Inc.
-
Biogen
-
bluebird bio, Inc.
-
Chiesi Farmaceutici S.p.A
-
CRISPR Therapeutics AG
-
Editas Medicine, Inc.
-
Gilead Sciences, Inc.
-
Intellia Therapeutics, Inc.
-
Jazz Pharmaceuticals, plc.
-
Juno Therapeutics, Inc
-
Merck KGaA
-
MolMed S.p.A.
-
Novartis Gene Therapies
-
Orchard Therapeutics plc
-
REGENXBIO Inc.
-
Sangamo Therapeutics, Inc.
-
Sarepta Therapeutics, Inc.
-
Sibiono GeneTech Co. Ltd.
-
Spark Therapeutics, Inc.
-
uniQure N.V.
-
Voyager Therapeutics